455 results match your criteria AIDS reviews[Journal]


Management of Polypharmacy and Drug-Drug Interactions in HIV Patients: A 2-year Experience of a Multidisciplinary Outpatient Clinic

AIDS Rev 2019 ;21(1):40-49

Gestione Ambulatoriale Politerapie Outpatient Clinic. ASST Fatebenefratelli Sacco University Hospital, Milan, Italy.

HIV-positive patients are treated with various antiretroviral-containing drug combinations to control their underlying disease, which may also be combined with drugs aimed to manage independent or secondary comorbidities. This can expose patients to drug-drug interactions (DDIs) that may lead to suboptimal drug exposure, an increased risk of therapeutic failure or poor tolerability, and a need to adopt alternative therapeutic strategies. Although such undesired responses to pharmacological therapies can be appropriately managed in some situations, the fact that the available information is usually incomplete which makes it difficult (if not impossible) to assess DDIs and the consequent adjustments of polytherapies in clinical practice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.24875/AIDSRev.19000035DOI Listing
January 2019

Sexually Transmitted Infections in Men having Sex with Men - Rising Numbers and Wider Etiologies

Authors:
Vicente Soriano

AIDS Rev 2019;21(1):50

Vicente Soriano UNIR Health Sciences School Madrid, Spain.

View Article

Download full-text PDF

Source
January 2019
3.787 Impact Factor

A Model for Potential B-cell Precursors of Broadly Neutralizing HIV-1 Antibodies Selection and Antibody Affinity Maturation

AIDS Rev 2019 ;21(1):23-27

Department of Experimental Oncology, National Cancer Research Center. Belgrade, Serbia.

The goal of this report was to propose a model, wherein synergy between the B-cell antigen receptor (BCR) and toll-like receptor (TLR) signaling is involved in the selection of the B-cell precursors of HIV-1 broadly neutralizing antibodies (bnAbs) with long heavy chain complementarity determining regions 3, from immature/transitional B cells. The model predicts the involvement of Ab/HIV-1 complexes in a way that Ab from the complex binds both BCRs and HIV-1, while on internalization of HIV-1 TLR ligands such as CpG motifs interacts with TLR9. The result of BCR and TLR9 orchestrated signaling is a formation of somatically mutated memory B cells potential precursors of bnAbs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.24875/AIDSRev.19000028DOI Listing
January 2019
1 Read

Gene Editing for HIV Cure at the Edge

Authors:
Vicente Soriano

AIDS Rev 2019;21(1):50a-51

UNIR Health Sciences School Madrid, Spain.

View Article

Download full-text PDF

Source
January 2019
3.787 Impact Factor

HIV Treatment Adherence - A Shared Burden for Patients, Health-Care Providers, and Other Stakeholders

AIDS Rev 2019 ;21(1):28-39

Department of Public Health, Federal Medical Centre, Yola, Adamawa State, Nigeria.

Successful HIV treatment is contingent on sustained high levels of treatment adherence. Several barriers to optimal adherence have been documented. In this article, we first review the global burden of non-adherence among HIV/AIDS positive individuals on a public health scale. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.24875/AIDSRev.19000037DOI Listing
January 2019

Neuropsychiatric Adverse Events with Dolutegravir and Other Integrase Strand Transfer Inhibitors

AIDS Rev 2019 ;21(1):4-10

Department of Infectious Diseases, University Hospital Germans Trias i Pujol; Fight AIDS Foundation, Badalona, Barcelona, Spain.

Neuropsychiatric adverse events (NPAEs) observed with the integrase strand transfer inhibitor (INSTI) dolutegravir (DTG) are usually mild to moderate. The most prevalent symptoms are insomnia and sleep disorders, but the spectrum also includes dizziness, anxiety, depression, headache, paraesthesia, muscle-skeletal pain, poor concentration, and slow thinking. In recent cohort studies involving >6400 patients in different countries, discontinuation rates due to NPAEs were observed in around 3. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.24875/AIDSRev.19000023DOI Listing
January 2019
3 Reads

HIV-1 and Compromised Adult Neurogenesis: Emerging Evidence for a New Paradigm of HAND Persistence

AIDS Rev 2019 ;21(1):11-22

Department of Pathology and Laboratory Medicine, Philadelphia, Pennsylvania, USA.

The face of the HIV-1/AIDS pandemic has changed significantly thanks to the development of antiretroviral therapy (ART) regimens. Unfortunately, several HIV-associated comorbidities continuously occur in the clinical population, most notably HIV-associated neurocognitive disorders (HAND). While many molecular and cellular mechanisms have been characterized by describing HAND pathology (specifically neuroinflammatory insults and oxidative stress) in the ART era, compromised adult neurogenesis is emerging as a potential new mechanism. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.24875/AIDSRev.19000003DOI Listing
January 2019
2 Reads

Hepatitis Delta Could Be More Frequent than Previously Thought.

AIDS Rev 2018;20(4):236

UNIR Health Sciences School and La Paz University Hospital Madrid, Spain.

View Article

Download full-text PDF

Source
January 2018
3.787 Impact Factor

Hepatitis E Virus, the Uninvited Intruder in Western Kitchens.

Authors:
Pablo Barreiro

AIDS Rev 2018;20(4):237-238

Hospital Carlos III- La Paz Madrid, Spain.

View Article

Download full-text PDF

Source
January 2018

New Dual Combination of Dolutegravir-Rilpivirine for Switching to Maintenance Antiretroviral Therapy.

Authors:
Esteban Ribera

AIDS Rev 2018 ;20(4):179-186

Department of Infectious Diseases, Hospital Universitari Vall d'Hebron and Universitat Autònoma de Barcelona, Barcelona, Spain.

Advances in antiretroviral therapy have led to dramatic improvements in survival of HIV-infected persons. However, HIV cure remains elusive and lifelong treatment is needed. Attempts for reducing long-term drug exposure, toxicities, and cost, while maintaining viral suppression, have led to explore whether maintenance strategies with less than triple therapy could be feasible using the newest more potent antiretrovirals. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.24875/AIDSRev.M18000026DOI Listing
January 2018
2 Reads

Rebound in Sexually Transmitted Infections Following the Success of Antiretrovirals for HIV/AIDS.

AIDS Rev 2018 ;20(4):187-204

Sexually Transmitted infections Unit, Centro Sanitario Sandoval. Madrid, Spain.

Nearly 1 million people become infected every day with any of the four major curable sexually transmitted infections (STIs), namely trichomoniasis, chlamydia, gonorrhea, and syphilis. Despite huge global incidence, STIs remain as neglected diseases. The success of antiretrovirals for halting progression to AIDS in HIV-infected individuals and for stopping HIV transmission to uninfected contacts, either as pre- or post-exposure -prophylaxis, has to lead to increased risky sexual behaviors through risk compensation. Read More

View Article

Download full-text PDF

Source
http://www.aidsreviews.com/resumen.php?id=1448
Publisher Site
http://dx.doi.org/10.24875/AIDSRev.18000034DOI Listing
January 2018
21 Reads

Toward the Cure of HIV-1 Infection: Lessons Learned and Yet to be Learned as New Strategies are Developed.

AIDS Rev 2018 ;20(4):220-225

Department of Neuroscience, Center for Translational AIDS Research, Philadelphia, USA.

Here, we review the progress that has been made in achieving a cure of HIV-1 infection. To date, this has only occurred in one person after he received allogeneic stem cell transplants from a CCR5 ∆32 homozygous donor in addition to chemotherapy and radiation to treat his acute myelocytic leukemia. The general consensus is that achieving a sustained remission of infection in the absence of antiretroviral therapy will involve a combination of strategies that involve both the targeting of the latent proviral genome and the induction of more effective anti-HIV-1 immune responses. Read More

View Article

Download full-text PDF

Source
http://www.aidsreviews.com/resumen.php?id=1450
Publisher Site
http://dx.doi.org/10.24875/AIDSRev.18000027DOI Listing
January 2018
12 Reads

Should HIV Patients be concerned about Occult Hepatitis B?

AIDS Rev 2018;20(4):238-239

UNIR Health Sciences School and La Paz University Hospital Madrid, Spain.

View Article

Download full-text PDF

Source
January 2018
3.787 Impact Factor

Longer Life Expectancy but still Accelerating Aging in HIV Patients under Antiretroviral Therapy.

AIDS Rev 2018;20(4):236a-237

UNIR Health Sciences School Madrid, Spain.

View Article

Download full-text PDF

Source
January 2018
3.787 Impact Factor

Economic Impact of HIV in the Highly Active Antiretroviral Therapy Era - Reflections Looking Forward.

AIDS Rev 2018 ;20(4):226-235

Research Institute for Evaluation and Public Policies (IRAPP); Universitat Internacional de Catalunya, Barcelona, Spain.

The main data on HIV in high-income countries from the standpoint of health economics are updated and discussed. Specifically, issues surrounding the economic impact of HIV are addressed for health care and occupational perspectives. We review the main epidemiological data on the prevalence of disease and foreseeable changes in patterns within the coming years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.24875/AIDSRev.M17000011DOI Listing
January 2018
2 Reads

Overcoming Obstacles in Lipid-lowering Therapy in Patients with HIV - A Systematic Review of Current Evidence.

AIDS Rev 2018 ;20(4):205-219

Department of Internal Medicine and Infectious Diseases. University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands.

Cardiovascular risk management in human immunodeficiency virus (HIV)-infected individuals is gaining increased attention due to the rising incidence and prevalence of cardiovascular disease in this population. Despite the availability of efficacious treatment strategies, implementation of guideline advocated preventive therapy, such as lipid-lowering therapy with statins, is hampered by perceived, expected, and real side effects as well as by expected interactions with combination antiretroviral therapy. These obstacles to optimal treatment have resulted in a large gap between the number of patients in whom lipid-lowering therapy is indicated and those actually taking lipid-lowering medication. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.24875/AIDSRev.18000016DOI Listing
January 2018
1 Read

Hot News: HTLV-1 Infection Still A Neglected Disease

Authors:
Vicente Soriano

AIDS Rev 2018;20(3):175

UNIR Health Sciences School and La Paz University Hospital Madrid, Spain.

View Article

Download full-text PDF

Source
February 2019
8 Reads
3.787 Impact Factor

Hot News: New insights from IeDEA and COHERE on global trends in CD4 counts at ART initiation

Authors:
George A Yendewa

AIDS Rev 2018 ;20(3):174-175

Division of Infectious Diseases and HIV Medicine Case Western Reserve University School of Medicine Cleveland, Ohio, USA.

View Article

Download full-text PDF

Source
February 2019
6 Reads

Non-Alcoholic Fatty Liver Disease in Patients with HIV Infection

AIDS Rev 2018 ;20(3):171-173

First Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece.

Non-alcoholic fatty liver disease (NAFLD) is highly prevalent in patients with HIV infection and appears to be more severe than in HIV-uninfected patients. Both metabolic (e.g. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.24875/AIDSRev.18000008DOI Listing
February 2019
9 Reads

Tolerability of Current Antiretroviral Single-Tablet Regimens

AIDS Rev 2018 ;20(3):141-149

Department of Internal Medicine, Infectious Diseases Unit, Hospital Universitari Joan XXIII, Universitat Rovira I Virgili, Tarragona, Spain.

The advent of protease inhibitors (PI) in the mid-nineties and its use as part of triple combinations revolutionized the management of HIV infection. Since then, progression to AIDS and AIDS-related deaths can be prevented. However, antiretroviral therapy based on PI has been discouraged for a while given its lower tolerability compared to alternative options; and only recent improvements in pharmacotherapy have renewed the interest for the newest agents within this class. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.24875/AIDSRev.M18000025DOI Listing
February 2019
20 Reads

Clinical Impact of Virological Failure and Resistance Analysis Definitions used in Pivotal Clinical Trials of Initial Antiretroviral Treatment: A Systematic Review

AIDS Rev 2018 ;20(3):158-170

Department of Internal Medicine, Hospital Nuestra Señora del Prado, Talavera de la Reina, Toledo, Spain.

There are no standardized criteria to characterize confirmed protocol-defined virological failure (PDVF) nor the inclusion criteria for the resistance analysis population (RAP) in Phase III randomized clinical trials (RCTs) of initial antiretroviral therapy (ART). We assessed the clinical impact of mismatching between virological non-response (HIV-1 RNA ≥50 copies/mL), confirmed PDVF (48 weeks), and RAP definition in studies with the newest first-line ART. A systematic review of all Phase III RCTs was performed, including preferred once-daily ART (EACS European AIDS guidelines) or recently approved by the US Food and Drug Administration. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.24875/AIDSRev.18000006DOI Listing
February 2019

Chronic Lung Disease in HIV Patients

AIDS Rev 2018 ;20(3):150-157

Modena HIV Metabolic Clinic, University of Modena and Reggio Emilia, Modena, Italy.

This narrative review discusses literature on chronic obstructive pulmonary disease (COPD) in people living with HIV (PLWH). Existing data indicate that HIV itself, independent of smoking, constitutes a pathogenic agent implicated in this disease condition. COPD can be viewed not exclusively as a pulmonary disease but rather as a systemic syndrome sparked and fueled by a persistent low-grade HIV-attributable inflammatory state. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.24875/AIDSRev.18000002DOI Listing
February 2019
18 Reads

Hot News: Dr. Robert Redfield Appointed as New CDC Director.

Authors:
Pablo Barreiro

AIDS Rev 2018 Apr-Jun;20(2):127

La Paz University Hospital, Madrid, Spain.

Well-known AIDS researcher Robert Redfield picked to lead the CDC on March 2018. He is one of the HIV/AIDS pioneers in the United States. During two decades at the Walter Reed Army Institute of Research, in Bethesda, MD, he made pivotal contributions, highlighting the importance of heterosexual HIV transmission, developing the Walter Reed staging system for HIV infection, and demonstrating that active HIV replication takes place during all stages of HIV disease. Read More

View Article

Download full-text PDF

Source
October 2018
20 Reads

Hot News: Hepatitis B Gene Therapy Coming to Age.

Authors:
Vicente Soriano

AIDS Rev 2018 Apr-Jun;20(2):125-127

La Paz University Hospital and UNIR Health Sciences School, Madrid, Spain.

The major pandemics caused by chronic viral infections is produced by HIV, hepatitis C virus (HCV), and hepatitis B virus (HBV), with estimates of 38, 70, and 250 million people worldwide, respectively (Fig. 1). During the last couple of years, the advent of direct oral antivirals has allowed pursuing global HCV eradication. Read More

View Article

Download full-text PDF

Source
October 2018
25 Reads
3.790 Impact Factor

Prevalence of Tuberculosis in HIV-positive Prisoners: A Systematic Review and Meta-analysis.

AIDS Rev 2018 Apr-Jun;20(2):114-124

Department of Epidemiology, Clinique médicale l'Actuel, Montreal, Canada.

Tuberculosis (TB) and HIV constitute the main burden of infectious diseases worldwide. Imprisonment is an important risk factor for contracting TB, especially among those living with HIV. This systematic review summarizes the available data on the prevalence of TB among HIV-positive prisoners; which may support improved targeted TB/HIV prevention plans. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.24875/AIDSRev.M18000023DOI Listing
October 2018
34 Reads
3.790 Impact Factor

HIV/AIDS in Sierra Leone: Characterizing the Hidden Epidemic.

AIDS Rev 2018 Apr-Jun;20(2):104-113

Department of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.

Sierra Leone is a low-income West African country that has dealt with waves of economic, political, and public health challenges in its recent past, including a decade-long brutal civil war and the Ebola epidemic of 2014-2016. The HIV/AIDS epidemic, which has raged on in the country since 1987, has long been characterized as stable. The latest UNAIDS report estimates a countrywide HIV prevalence rate of 1. Read More

View Article

Download full-text PDF

Source
http://www.aidsreviews.com/resumen.php?id=1429
Publisher Site
http://dx.doi.org/10.24875/AIDSRev.M18000022DOI Listing
October 2018
24 Reads

The Role of HIV in the Progression through the Stages of the Human Papillomavirus to Cervical Cancer Pathway.

AIDS Rev 2018 Apr-Jun;20(2):94-1043

Department of Epidemiology, Florida International University, Miami, Florida, United States.

Globally, an estimated 36.9 million persons are living with HIV/AIDS, and approximately 291 million women worldwide are carriers of human papillomavirus (HPV). A large number of women currently infected with either or both viruses constitute a large burden on the national health care system. Read More

View Article

Download full-text PDF

Source
http://www.aidsreviews.com/get.php?x=aids_2018_20_2_094-103.
Publisher Site
http://dx.doi.org/10.24875/AIDSRev.M18000021DOI Listing
October 2018
34 Reads

Is UNAIDS 90-90-90 target a Dream or a Reality for Middle East and North Africa Region on Ending the AIDS Epidemic? A Review Study.

AIDS Rev 2018 Apr-Jun;20(2):83-93

Center for Health Related Social and Behavioral Sciences Research, Shahroud University of Medical Sciences, Shahroud, Iran.

Middle East and North Africa (MENA) region is lagging far behind the global average to reach 90-90-90 targets. This study uses the UNAIDS 90-90-90 program to evaluate the HIV current situation in MENA countries, and understand the challenges that exist in the way of approaching the program goals. All articles and publications were searched based on the 90-90-90 program indexes among national and international data resources such as official national reports and online scientific databases such as PubMed, Medline, and Scopus up to December 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.24875/AIDSRev.M18000020DOI Listing
October 2018
133 Reads
3.787 Impact Factor

A Comprehensive Development Agenda on Tenofovir Alafenamide in Clinical Practice.

AIDS Rev 2018 Apr-Jun;20(2):75-82

Division of Infectious Diseases, ASST Papa Giovanni XXIII, Bergamo, Italy.

The introduction of tenofovir (TFV) alafenamide (TAF) into clinical practice will be a further revolution in antiretroviral therapy. Currently available HIV-1 regimens are wide enough to allow diversified usage in different settings. Despite the fact that TAF is not capillary accessible, even in industrialized countries, ultimate International Guidelines have already included TAF in backbone or in single-tablet regimens. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.24875/AIDSRev.M18000017DOI Listing
October 2018
4 Reads

State of the Art in HIV Drug Resistance: Science and Technology Knowledge Gap.

AIDS Rev 2018 Jan-Mar;20(1):27-42

KU Leuven - University of Leuven, Department of Microbiology and Immunology, Rega Institute for Medical Research, Clinical and Epidemiological Virology, Leuven, Belgium.

Resistance to antiretroviral therapy (ART) threatens the efficacy of human immunodeficiency virus type 1 (HIV-1) treatment. We present a review of knowledge gaps in the science and technologies of acquired HIV-1 drug resistance (HIVDR) in an effort to facilitate research, scientific exchange, and progress in clinical management. The expert authorship of this review convened to identify data gaps that exist in the field of HIVDR and discuss their clinical implications. Read More

View Article

Download full-text PDF

Source
October 2018
3 Reads

State of the Art in HIV Drug Resistance: Surveillance and Regional Gaps.

AIDS Rev 2018 Jan-Mar;20(1):43-57

KU Leuven - University of Leuven, Department of Microbiology and Immunology, Rega Institute for Medical Research, Clinical and Epidemiological Virology, Leuven, Belgium.

This article is the second of a two-part review aiming to identify gaps in the knowledge and management of human immunodeficiency virus type 1 drug resistance (HIVDR) from global and regional perspectives. Here, we examine the policy and programmatic gaps in HIVDR surveillance, the affected populations and settings, and implications for clinical practice. The expert authorship of this review convened to identify gaps in HIVDR surveillance, with a particular focus on specific regional variations within and between Europe and Asia, to highlight directions for research and implementation. Read More

View Article

Download full-text PDF

Source
October 2018
6 Reads

Hot News: Impact of Low-level Viremia on Treatment Outcomes During ART - Is it Time to Revise the Definition of Virological Failure?

AIDS Rev 2018 Jan-Mar;20(1):71-72

Infectious Diseases Unit, Department of Internal Medicine, Complexo Hospitalario Universitario de Vigo, IIS Galicia Sur, SERGAS-UVigo, Spain.

The level of HIV-RNA in plasma (HIV viral load) is the main marker used to monitor the virological response to antiretroviral therapy (ART) in HIV-infected patients. The threshold used to define virological suppression has historically been dictated by the limits of detection of the commercial assays used to quantify the plasma viral load. Thus, as more sensitive assays have proliferated and become more widely available, the definition has shifted from < 400 cop/mL with the first generation assays, to < 50 cop/mL, to < 20 cop/mL currently. Read More

View Article

Download full-text PDF

Source
October 2018
2 Reads

Hot News: Sexually Transmitted Infections on the Rise in PrEP Users.

Authors:
Pablo Barreiro

AIDS Rev 2018 Jan-Mar;20(1):71

Carlos III-La Paz University Hospital, Madrid, Spain.

Pre-exposure prophylaxis (PrEP) with oral Truvada (tenofovir plus emtricitabine) is effective at preventing HIV infection in high-risk homosexual men. In the United States, PrEP was approved in 2012 and is reimbursed by Medicaid and the majority of private insurers. The situation is diverse and not uniform in the European Union, being PrEP more widely used in France than in the rest of countries. Read More

View Article

Download full-text PDF

Source
October 2018

Dolutegravir Neuropsychiatric Adverse Events: Specific Drug Effect or Class Effect.

Authors:
Jean Cyr Yombi

AIDS Rev 2018 Jan-Mar;20(1):14-26

Department of Internal Medicine and Infectious Diseases, AIDS Reference Centre, Cliniques Universitaires Saint Luc, Université Catholique de Louvain, Belgium.

Integrase strand transfer inhibitors (INSTIs) are a newer class of antiretroviral treatment for HIV-infected patient. INSTIs currently available for use are raltegravir, elvitegravir, dolutegravir (DTG), and bictegravir. Clinical studies using INSTIs have demonstrated an 80-90% efficiency in treating HIV-positive antiretroviral therapy - naive patients. Read More

View Article

Download full-text PDF

Source
October 2018
19 Reads

Antiretroviral Therapy in Advanced HIV Disease: Which is the Best Regimen?

AIDS Rev 2018 Jan-Mar;20(1):3-13

Department of Infectious Diseases, Hospital Universitari Vall d'Hebron, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain.

Advanced HIV disease, defined as a CD4 cell count below 200 cells/μl or the presence of an AIDS-defining illness, remains common among HIV-infected individuals who first present for medical care. In developed countries, nearly 30% of new HIV diagnoses occurred at advanced stages of the disease, and it is important because advanced HIV disease has been associated with worse clinical outcomes, including lower rates of virological response, higher morbidity, and higher mortality. However, there are scarce data regarding which is the best antiretroviral regimen in these patients. Read More

View Article

Download full-text PDF

Source
October 2018
2 Reads

Report from the International Conference on Viral Hepatitis - 2017.

AIDS Rev 2018 Jan-Mar;20(1):58-70

Liver Unit, Rush University Medical Center, Chicago, IL, USA.

The International Conference on Viral Hepatitis 2017 brought exciting news on the treatment of viral hepatitis. The most recent estimates of the burden for hepatitis B virus and hepatitis C virus (HCV) infections were presented. The current gaps and prospects for regional and global eradication of viral hepatitis were discussed on the light of the WHO roadmap until 2030. Read More

View Article

Download full-text PDF

Source
October 2018
9 Reads
3.790 Impact Factor

Hot News: HIV Epidemics - Current Burden and Future Prospects.

AIDS Rev 2017 Oct-Dec;19(4):239

Puerta de Hierro Research Institute, Majadahonda, Spain.

The latest estimate from the WHO is of nearly 37 million people living with HIV worldwide by the end of 2016. Roughly 20 million are receiving antiretroviral therapy. Despite this progress in diagnosis and treatment, nearly 2 million new HIV infections continue to occur annually. Read More

View Article

Download full-text PDF

Source
January 2018
6 Reads

Treatment as Prevention: Should Hepatitis C Learn the Lessons from HIV?

AIDS Rev 2017 Oct-Dec;19(4):212-218

Department of Infectious Diseases, University Hospital Crosshouse, Kilmarnock, Scotland, UK.

Long-term experience in the treatment of HIV-infected individuals has shown indirect benefits of early initiation of antiretroviral therapy, particularly in preventing HIV transmission. With the advent of direct-acting antivirals for the treatment of hepatitis C, the strategy of treatment-as-prevention has become feasible. However, economic, clinical, ethical, and public health issues arise from the concept of using therapeutic interventions only as prevention strategies. Read More

View Article

Download full-text PDF

Source
January 2018
5 Reads

Non-Alcoholic Fatty Liver Disease and HIV/AIDS: A New Way of Modulation of Cardiovascular Risk.

AIDS Rev 2017 Oct-Dec;19(4):190-197

Department of HIV and Genitourinary Medicine, Milton Keynes University Hospital, NHS Foundation Trust, Milton Keynes, UK.

With the advent and subsequent success of antiretroviral therapy, HIV infection has largely become a chronic condition and is increasingly seen alongside metabolic disorders such as dyslipidemia and insulin resistance. Furthermore, the administration of antiretroviral therapy itself is associated with an increase in the incidence of metabolic risk factors, namely insulin resistance, lipoatrophy, dyslipidemia, and abnormalities of fat distribution, in HIV patients. Thus, further challenges in the management of HIV patients include the management of diabetes and the metabolic syndrome, non-alcoholic fatty liver disease. Read More

View Article

Download full-text PDF

Source
January 2018
6 Reads

Rilpivirine: The Key for Long-term Success.

Authors:
Pompeyo Viciana

AIDS Rev 2017 Oct-Dec;19(3):156-166

Clinical Unit of Infectious Diseases, Microbiology, and Preventive Medicine, HIV and PK Research Group, Institute of Biomedicine of Seville (IBiS), University of Seville, CSIC, University Hospital Virgen del Rocío, Sevilla, Spain.

During the past 30 years of antiretroviral therapy, continuous improvements in drug discovery have provided increasingly potent and safer antivirals that have transformed HIV infection in a chronic illness, rarely fatal. Non-nucleoside reverse-transcriptase inhibitors (NNRTIs) are frequently used as part of any antiretroviral combination therapy. Side effects and low resistance barrier of fi rst-generation NNRTIs (e. Read More

View Article

Download full-text PDF

Source

Hot News: Ready for HIV Dual Therapy? - New Data from International HIV/AIDS Society 2017.

AIDS Rev 2017 Oct-Dec;19(3):167-172

Case Western Reserve University School of Medicine, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.

The introduction of combination antiretroviral therapy (ART) in the 1990s has fundamentally transformed the landscape of HIV medicine, greatly improved disease morbidity and mortality, and reduced transmission rates across all demographic groups. Central to this success was the idea that to achieve best disease outcomes and minimize the development of drug resistance, at least three antiretroviral agents should be used for HIV treatment. This therapeutic strategy is a core tenet of HIV medicine, backed by incontrovertible scientific evidence, and made easy to deploy by the high compliance levels with once-daily coformulations, which have generally been well tolerated. Read More

View Article

Download full-text PDF

Source
June 2018
5 Reads

Hot News: Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.

Authors:
Vicente Soriano

AIDS Rev 2017 Oct-Dec;19(3):167-172

Infectious Diseases Unit, La Paz University Hospital, Madrid, Spain.

The huge success of current antiretroviral therapy is mediated by a triple effect: (i) Halting progression to AIDS in infected persons; (ii) reducing the risk of transmission to contacts (treatment as prevention); and (iii) minimizing the risk of HIV acquisition treating uninfected persons at risk (pre-exposure prophylaxis). However, UNAIDS has estimated that only 70% of infected people globally are diagnosed, only 53% are treated, and overall 44% have undetectable viral load, which is the necessary request for ensuring any antiretroviral benefit. Thus, with 37 million people currently living with HIV worldwide and more than 2 million new infections per year, the prospects for global HIV eradication are far on the horizon. Read More

View Article

Download full-text PDF

Source
June 2018
74 Reads
3.790 Impact Factor

Hot News: Exosomes as New Players in HIV Pathogenesis - New Data from the IAS 2017.

AIDS Rev 2017 Oct-Dec;19(3):173-175

Division of Infectious Diseases, Case Western Reserve University, Cleveland, Ohio, USA.

Exosomes are nanovesicles that can be released into the extracellular medium by different cell types and are considered an important system of intercellular communication. In some instances, on secretion, exosomes break down and release their content into the extracellular space. Alternatively, intact exosomes can interact with other cells and discharge their content directly into the target cell cytoplasm. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5828156PMC
June 2018
4 Reads

Generics for the Treatment of Hepatitis C in Monoinfected and HIV-coinfected Patients: Pros and Cons.

AIDS Rev 2017 Oct-Dec;19(3):167-172

Department of Infectious Diseases, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy.

The treatment of hepatitis C virus in monoinfected and HIV-coinfected patients has greatly changed over recent years as a result of the introduction of direct-acting antiviral agents (DAAs), which have revolutionized clinical outcomes and led to sustained virological response rates above 90-95%. The discovery of new molecules and the subsequent competition between pharmaceutical companies, together with the negotiated price policies pursued by many national health systems, have led to a gradual reduction in the cost of DAAs, and expand their use to an increasing number of patients, including those with mild liver damage. However, the cost of branded DAAs is still too high for many developing countries, and many patients are still left without therapy. Read More

View Article

Download full-text PDF

Source
June 2018
5 Reads

Mechanisms of accelerated liver fibrosis in HIV-HCV coinfection.

AIDS Rev 2017 Oct-Dec;19(3):148-155

First Department of Internal Medicine, AHEPA Hospital, Aristotle University of Thessaloniki, School of Medicine, 546 36 Thessaloniki, Greece.

Although there is evidence that HCV progresses rapidly in HIV/HCV coinfected patients in comparison with HCV monoinfected, the HIV-, HCV- and host/genetic-related factors, as well as the exact mechanisms implicated in this process are not fully elucidated. Furthermore, cure of HCV in those coinfected seems possible with the new antiviral drugs, but high cost as well as insufficient identification, linkage with care and treatment hamper the achievement of this goal. Research on the subject, could reveal an important prognostic marker for the effectiveness of persuasion of patients with HIV/HCV coinfection with a predicted accelerated fibrosis course, in order to facilitate and prioritize, not in terms of guidelines but in the real life situation, their treatment with a medically just framework. Read More

View Article

Download full-text PDF

Source
June 2018
21 Reads

HIV and HCV in U.S. Prisons and Jails: The Correctional Facility as a Bellwether Over Time for the Community's Infections.

AIDS Rev 2017 Oct-Dec;19(3):134-147

Rollins School of Public Health, Emory University, Atlanta GA, USA.

Screening and treating correctional populations for HIV and HCV infections is essential to successfully addressing both epidemics in the USA. The prevalence of HIV and HCV infection is high in prisons and jails due to increased rates of incarceration among disproportionately affected groups such as injection drug users. Through a search of the published and grey literature and surveying persons overseeing health programs in prisons, we collected data on efforts to determine prevalence first for HIV and then for HCV. Read More

View Article

Download full-text PDF

Source
June 2018
10 Reads
1 Citation
3.790 Impact Factor

Novelties in Evaluation and Monitoring of Human Immunodeficiency Virus-1 Infection: Is Standard Virological Suppression Enough for Measuring Antiretroviral Treatment Success?

AIDS Rev 2017 Oct-Dec;19(3):119-133

Department of System Medicine, Clinic of Infectious Diseases, University Hospital "Tor Vergata", Rome, Italy.

The high potency and tolerability of the currently available antiretroviral drugs has modified HIV-1 infection from a life-threatening disease to a chronic illness. Nevertheless, some issues still remain open to optimize the management of HIV-1 infected patients in term of maintenance of virological suppression over time, identifying patients that could benefit from simplification therapy, and reducing co-mordibities driven by chronic inflammation. The availability of robust and affordable virological and immunological markers can help in solving these issues by providing information on the burden of HIV-1 reservoir in all the anatomical compartments in which the virus replicates as well as on persistent inflammation, immune activation and senescence despite successful virological suppression. Read More

View Article

Download full-text PDF

Source
June 2018
1 Read

Obituary: HIV/AIDS researcher Mark Wainberg passed away.

AIDS Rev 2017 Apr - Jun;19(2):115

Infectious Diseases Department, La Paz University Hospital, Madrid, Spain.

View Article

Download full-text PDF

Source
July 2017
6 Reads
3.790 Impact Factor

Darunavir Stands Up as Preferred HIV Protease Inhibitor.

Authors:
Josep Mallolas

AIDS Rev 2017 Apr - Jun;19(2):105-112

HIV/AIDS Unit, Infectious Disease Service, Hospital Clínic, University of Barcelona, Barcelona, Spain.

Current antiretroviral therapy reaches and maintains viral suppression over the years in more than 90% of treated HIV-infected individuals. Although integrase inhibitors are the preferred third agent in antiretroviral therapy in the current guidelines, rilpivirine, a non-nucleoside reverse transcrip- tase inhibitor, and darunavir (DRV), a second-generation protease inhibitor, are the preferred third companion to be used along with a backbone of two nucleos(t)ide reverse transcriptase inhibitors as first-line triple HIV combination treatment. However, rilpivirine is not recommended in patients with plasma HIV-RNA above 100,000 copies/mL. Read More

View Article

Download full-text PDF

Source
February 2018
8 Reads